DV
Dividend Vision

RPRX — Royalty Pharma PLC

Royalty Pharma PLC (RPRX)

RPRX pays a 1.54% distribution rate, quarterly. Its Distribution Safety Score™ is 100 (Safe), giving a Safety-Adjusted Yield of 1.54%. Distributions grew 8.3% over the past year. Total return is 137.9% over the past 6.2 years, 26.1 points behind SPY at 164.0%. Its deepest 1-year drawdown was 6.1%.

Royalty Pharma PLC purchases biopharmaceutical royalties and funds innovation in the industry, holding royalty interests in approximately 35 marketed therapies and 20 development-stage drug candidates across therapeutic areas including rare disease, oncology, neuroscience, and diabetes. The company distributes cash quarterly at a modest current distribution rate. This business appeals to income-focused investors seeking exposure to the biopharmaceutical sector through royalty cash flows rather than traditional drug development or commercialization.

RPRX key facts

Distribution Safety Score™
100 · Safe
Safety-Adjusted Yield
1.54%
Asset type
Stock
Asset class
Equity
Inception date
06/09/2020
Distribution rate
1.54%
Distribution frequency
Quarterly
Trailing yield
1.58%
5-year average yield
2.29
Last close
$58.60
Market cap
$33,861,156,864
Average volume
1596476.0
Last dividend
$0.2350
Ex-dividend date
08/14/2026
Payment date
09/10/2026
Beta
0.425
Payout ratio
0.1759
P/E ratio
31.5054
Forward P/E
44.843
EPS
$1.86